Rybelsus® tablets re-classified as a special container
Following representations from Community Pharmacy England, with the support of Novo Nordisk Ltd, the Department of Health of Social Care (DHSC) has re-determined the special container status of Rybelsus® (semaglutide) tablets. From 1 April 2024, all three strengths of Rybelsus® tablets (3mg, 7mg and 14mg) will be re-classified as special containers to be supplied as
Read more